Researchers will present new findings on whether giredestrant, a potential therapy currently being studied in a phase 3 clinical trial, worked similarly before and after menopause in early-stage breast cancer at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Giredestrant, developed by Roche, is an investigational oral treatment for hormone-sensitive breast cancer. The focus on menopausal status may matter because hormone levels and treatment approaches can differ before and after menopause.
The upcoming presentation will share results from the phase 3 lidERA Breast Cancer trial, which studied patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer. This type of cancer may grow in response to estrogen but does not have high levels of HER2, a growth-related protein found on some breast cancer cells.
ER-positive, HER2-negative breast cancer is one of the most common types of breast cancer. Roche, the pharmaceutical company developing giredestrant, said this subtype accounts for about 70% of all cases.
Giredestrant targets and breaks down estrogen receptors. The drug is part of a class of treatments called selective estrogen receptor degraders, or SERDs.
Read more about breast cancer treatment and care
Roche previously reported in December 2025 that the lidERA trial showed a 30% reduction in the risk of invasive disease recurrence or death with giredestrant compared with standard endocrine therapy. The new ASCO findings follow those earlier results.
“In early ER-positive breast cancer, challenges with disease recurrence and treatment adherence mean there is an urgent need for more effective, tolerable endocrine therapies,” said Dr. Aditya Bardia, lidERA principal investigator.
At three years, 92.4% of people treated with giredestrant were alive and free of invasive disease. The rate was 89.6% with standard endocrine therapy. Roche also reported that the benefit was consistent across clinically relevant subgroups.
Researchers will present the analysis by menopausal status orally on May 30 during a breast cancer session focused on local, regional and adjuvant treatment. Roche has also submitted the results to the U.S. Food and Drug Administration for review.
Sign up here to get the latest news, perspectives, and information about breast cancer sent directly to your inbox. Registration is free and only takes a minute.
